BioLoomics: Funding, Investors & Team (Aug 2026)
BioLoomics is a biotech firm at the preclinical phase that applies a microscope-based evolution method to manufacture protein-based medication detection techniques and medicines. With the VariVolve mechanism, we can evaluate millions of protein designs within hours to identify activity target, making it possible to extract more sought after protein design results from the extensive chemical constellation. The primary advantage with the BioLoomics approach is the utilization of whole, unfragmented cells as experimental mediums that gather intricate drug behavior results that are otherwise impossible to obtain through traditional laboratory tests.
BioLoomics has raised $18.0M across 2 funding rounds on record, the most recent a Seed of $8.7M announced in Sep 2023.
That round is in line with the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
BioLoomics Company Profile and Key Stats
Latest funding round on record: Sep 2023.
BioLoomics Funding Rounds
BioLoomics raised $9.3M in an undisclosed round announced in Mar 2023.
6 months later, a Seed of $8.7M was announced in Sep 2023.
BioLoomics Founders and Leadership Team
No contact details are on record for this team yet.
BioLoomics Funding Compared to Other Biotechnology Startups
BioLoomics' latest round of $8.7M is in line with the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like BioLoomics in Biotechnology and Boulder
Companies Similar to BioLoomics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
BioLoomics Funding FAQs
What does BioLoomics do?
BioLoomics is a biotech firm at the preclinical phase that applies a microscope-based evolution method to manufacture protein-based medication detection techniques and medicines. With the VariVolve mechanism, we can evaluate millions of protein designs within hours to identify activity target, making it possible to extract more sought after protein design results from the extensive chemical constellation. The primary advantage with the BioLoomics approach is the utilization of whole, unfragmented cells as experimental mediums that gather intricate drug behavior results that are otherwise impossible to obtain through traditional laboratory tests.
How much funding has BioLoomics raised?
BioLoomics has raised $18.0M across 2 rounds on record. The most recent is a Seed of $8.7M announced in Sep 2023.
When did BioLoomics last raise funding?
BioLoomics' most recent funding round on record is a Seed of $8.7M, announced in Sep 2023.
Who is the CEO of BioLoomics?
Doug Chapnick is listed as CEO at BioLoomics.
Where is BioLoomics headquartered?
BioLoomics is based in Boulder, Colorado, United States.
How many employees does BioLoomics have?
BioLoomics is in the 1-10 employee band.
How does BioLoomics' funding compare to other Biotechnology startups?
BioLoomics' latest round of $8.7M is in line with the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's BioLoomics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for BioLoomics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.